ESC Premium Access

Using empagliflozin in your patients with type 2 diabetes: considerations for daily patient care.

Topic: Diabetes, dysglycaemia and metabolic syndrome
Sponsored by Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Congress Presentation

About the speaker

Doctor Jacob Allan Udell

Women's College Hospital, Toronto (Canada)
8 presentations
0 follower

6 more presentations in this session

Introduction – Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Managing cardiovascular outcomes in patients with type 2 diabetes – Where have we come from and where are we going?

Speaker: Professor D. McGuire (Dallas, US)

Thumbnail

Cardiovascular risk reduction with empagliflozin: exploring the evidence from EMPA-REG OUTCOME®.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Thumbnail

Experience with empagliflozin: insights from practice.

Speaker: Professor N. Marx (Aachen, DE) Professor D. McGuire (Dallas, US) Professor F. Zannad (Vandoeuvre-Les-Nancy, FR) Doctor J. Udell (Toronto, CA)

Thumbnail

Chair’s summary and audience Q&A.

Speaker: Professor N. Marx (Aachen, DE)

Thumbnail

Access the full session

Improving cardiovascular outcomes in patients with type 2 diabetes: where does the evidence lead us?

Speakers: Doctor J. Udell, Professor N. Marx, Professor D. McGuire, Professor F. Zannad, Professor N. Marx...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk